04:10 AM EDT, 09/09/2024 (MT Newswires) -- (Updates to include the company's recent stock movement in the last paragraph.)

Johnson & Johnson ( JNJ ) said Sunday that extended data from a phase 3 study of its lung cancer combination therapy showed consistent benefit across long-term outcomes compared with osimertinib monotherapy.

The study showed that Johnson & Johnson's ( JNJ ) therapy, Rybrevant combined with Lazcluze, strongly improved overall survival in adult patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations at about three years of follow-up.

At three years, 61% of patients receiving Rybrevant combined with Lazcluze were alive compared to 53% of those treated with osimertinib.

The company said the overall survival would continue to be assessed with longer-term follow-up as a key secondary endpoint.

Shares of the company declined 0.4% in recent premarket trading activity.

Price: 164.38, Change: -0.61, Percent Change: -0.37